ASPPH logo

Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________

Department of Health and Human Services – Centers for Disease Control – OSTLTS Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health

Proposal Due Date:                                               March 5, 2021

Expected Number of Awards:                            15

Estimated Total Program Funding:                  $750,000

Award Ceiling:                                                        $250,000

Award Floor:

Funding Opportunity Number:                          CDC-RFA-OT18-18020301SUPP21

Purpose: The purpose of this notice of funding opportunity (NOFO) is to announce the availability of supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health. This supplemental funding opportunity will support recipients in delivering capacity-building assistance (CBA) activities to address ongoing needs for the COVID-19 response. The CDC-RFA-OT18-1802 recipients are eligible to submit applications for COVID-19 CIO Project Plans that match the Target Population Category (A, B, or C) and Target Population Description for which they received initial funding in FY18. The COVID-19 CIO Project Plans will be attached to the NOFO once published.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331035

________________________________________________________

Department of Health and Human Services – National Institutes of Health – National Institute on Alcohol Abuse and Alcoholism – SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              March 14, 2021

Proposal Due Date:                                                           April 14, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number:                                      NOT-AA-21-002

Purpose: This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This RFA uses a three-year R01 mechanism.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-002.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – National Institute on Alcohol Abuse and Alcoholism – SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              March 14, 2021

Proposal Due Date:                                                           April 14, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:                                                                    $50,000

Award Floor:

Funding Opportunity Number:                                      NOT-AA-21-003

Purpose: This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-003.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              March 14, 2021

Proposal Due Date:                                                           April 14, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number:                                      NOT-AA-21-004

Purpose: This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-004.html

________________________________________________________

Department of Health and Human Services – National Institute of Health – Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control

Proposal Due Date:                                                           March 31, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number:                                      NOT-CA-21-033

Purpose: Studies should contribute to understanding the impact of COVID-19 on global cancer prevention and control. This may include the direct effects of COVID-19 in cancer patients or the indirect health, economic, and sociocultural impacts of the pandemic across the cancer continuum.

Studies that generate an evidence base necessary to mitigate the effects of this and future pandemics on persons with cancer, at risk for cancer, undergoing treatment for cancer, or in remission are especially encouraged.

Specific Areas of Research Interest:

Possible research interests include, but are not limited to, the following areas:

Implementation studies to understand the impact of COVID-19 on the adoption, adaptation, integration, implementation, scale-up and/or sustainability of evidence-based interventions, tools, policies, and guidelines in cancer prevention, detection, diagnosis, treatment, and survivorship in LMICS, including:

Studies to understand and describe innovations in the implementation of care delivery in low-resource settings developed as a result of the pandemic with a potential for global relevance (so-called ‘frugal innovations’), as well as studies to understand multi-level factors and processes influencing the acceptability, adoption, adaptation, feasibility, integration, implementation, scale-up, and/or sustainability of such innovations;

Studies to understand the feasibility, acceptability, and/or barriers to implementation of telemedicine and mobile health applications that aim to facilitate interaction between cancer patients and providers in the absence of in-person health visits.

Studies to understand and describe adaptations and/or delivery of digital health technologies, including mobile health and telemedicine tools, developed for detection, diagnosis, treatment, or prevention of cancer at the point-of-care, or that reduce or eliminate barriers to timely care resulting from the COVID-19 pandemic, inclusive of, but not limited to:

Point-of-care in vitro diagnostics;

Self-care technologies, including self-screening;

Patient navigation and care triage;

Bioinformatics and information technologies;

Clinical decision support technologies.

Studies to generate and/or assess the use of evidence-based decision tools or models to inform decisions related to efficient utilization of existing and emerging technologies such as those listed above, and strategies for cancer control in the context of the COVID-19 pandemic in LMICs, inclusive of, but not limited to:

The impact of COVID-19 on health and research outcomes in cancer patients and/or cancer survivors;

The impact of COVID-19 on cancer screening, including strategies for recovery;

The long-term impact of COVID-19 or future pandemics on cancer risk, incidence, and mortality.

Studies seeking to understand the psycho-social impacts of COVID-19 on health-seeking behaviors of groups suffering from or at risk for cancer, inclusive of, but not limited to:

The influence of cancer-related stigma on health-seeking behaviors;

The influence of COVID-19 on care-seeking pathways for cancer primary prevention, secondary prevention, and treatment;

The impact of COVID-19 stigma on the mental health of healthcare workers and its effect on care delivery.

Studies seeking to understand the impact of COVID-19 on prevention, diagnosis, treatment, and outcomes of HIV-associated malignancies.

Within the above research interests, studies that aim to generate evidence on the mitigation of negative impacts of future health emergencies are strongly encouraged.

Applicants are strongly encouraged to contact the NCI Program Director of the parent award to discuss potential applications and whether urgent competitive revision applications or administrative supplement requests are more appropriate for the proposed research.

https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-033.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

Proposal Due Date:                                                           June 1, 2021

Expected Number of Awards:                                        75

Estimated Total Program Funding:                              $35,000,000

Award Ceiling:                                                                    $600,000

Award Floor:

Funding Opportunity Number:                                      PAR-21-127

Purpose: The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.

https://grants.nih.gov/grants/guide/pa-files/PAR-21-127.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)

Proposal Due Date:                                                           June 1, 2021

Expected Number of Awards:                                        25

Estimated Total Program Funding:                              $30,000,000

Award Ceiling:                                                                    $2,000,000

Award Floor:

Funding Opportunity Number:                                      PAR-21-126

Purpose: The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, biomedical imagers, high throughput robotic screening systems, X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, and cell sorters.

https://grants.nih.gov/grants/guide/pa-files/PAR-21-126.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

Proposal Due Date:                                                           June 1, 2021

Expected Number of Awards:

Estimated Total Program Funding:                              $3,000,000

Award Ceiling:                                                                    $250,000

Award Floor:

Funding Opportunity Number:                                      PAR-21-125

Purpose: The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received substantial S10 instrumentation awards of a total of $250,001 or greater in any of Federal fiscal years 2018-2020. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.

https://grants.nih.gov/grants/guide/pa-files/PAR-21-125.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              30 days prior to application due date

Proposal Due Date:                                                           June 4, 2021

Expected Number of Awards:                                        1

Estimated Total Program Funding:                              $1,800,000

Award Ceiling:                                                                    $1,200,000

Award Floor:

Funding Opportunity Number:                                      RFA-AI-20-080

Purpose:  The goal of this FOA is to support a Coordinating Center for the Human Immunology Project Consortium (HIPC) program.  The HIPC program, supported through a separate FOA, will consist of 5-8 multi-project cooperative agreement (U19) awardees that will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The HIPC Coordinating Center supported by this FOA will be responsible for: coordinating cross-HIPC data integration, analysis, and visualization; developing and maintaining a public HIPC website and knowledgebase to support cross-HIPC data analysis and visualization; and fostering collaborations amongst HIPC-funded investigators by managing the HIPC subcommittees and an Infrastructure and Opportunity Fund to support collaborative studies.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-080.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Human Immunology Project Consortium (U19 Clinical Trial Optional)

Letter of Intent Due Date:                                              30 days prior to application due date

Proposal Due Date:                                                           June 4, 2021

Expected Number of Awards:

Estimated Total Program Funding:                              $16,000,000

Award Ceiling:                                                                    $1,500,000

Award Floor:

Funding Opportunity Number:                                      RFA-AI-20-079

Purpose: This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort.  A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-079.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)

Letter of Intent Due Date:                                              May 10, 2021

Proposal Due Date:                                                           June 10, 2021

Expected Number of Awards:

Estimated Total Program Funding:                              $18,000,000

Award Ceiling:                                                                    $650,000

Award Floor:

Funding Opportunity Number:                                      RFA-TR-21-009

Purpose: This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin and to develop a catalog of VOCs as distinct signatures for at least 20 human diseases and conditions. These sensing devices must be able to associate VOC patterns using artificial intelligence to patients with various conditions for diagnostic purposes along with capabilities to incorporate and integrate vital signs. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology, Gas Chromatography (GC) or any sensing technology able to detect VOC patterns associated with disease. This new program is called SCENT, which stands for Screening for Conditions by E-Nose Technology. To ensure project success, this FOA requires multidisciplinary collaborations and a team science approach. Groups may include a combination of the following: Biomedical engineers, material scientists, biosensing experts, software engineers, chemists, clinicians, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.

https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-009.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 – Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              May 18, 2021

Proposal Due Date:                                                           June 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:                              $1,675,000

Award Ceiling:                                                                    $100,000

Award Floor:

Funding Opportunity Number:                                      RFA-RM-21-011

Purpose:  Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.

https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-011.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 – Clinical Trial Not Allowed)

Proposal Due Date:                                                           July 14, 2021

Expected Number of Awards:                                        4-7

Estimated Total Program Funding:                              $3,500,000

Award Ceiling:

Award Floor:

Funding Opportunity Number:                                      RFA-DA-22-004

Purpose: The purpose of this FOA is to support exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. The FOA aims to promote research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-004.html

________________________________________________________

Department of Health and Human Services – National Institutes of Health – High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 – Clinical Trials Not Allowed)

Letter of Intent Due Date:                                              August 15, 2021

Proposal Due Date:                                                           September 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:                                                                    $400,000

Award Floor:

Funding Opportunity Number:                                      RFA-DA-22-006

Purpose: This FOA will support high-throughput screening or similar transformative approaches to identify novel receptors, signal transducers, or small molecules that modulate SUD-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway).  These projects may also include secondary screens and/or validation of key hits identified.

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-006.html